The new era of adjuvant therapies for melanoma
- 30 May 2018
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 15 (9), 535-536
- https://doi.org/10.1038/s41571-018-0048-5
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerationsEuropean Journal of Cancer, 2018
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III MelanomaThe New England Journal of Medicine, 2018
- Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trialThe Lancet Oncology, 2018
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaThe New England Journal of Medicine, 2017
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated MelanomaThe New England Journal of Medicine, 2017
- Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017European Journal of Cancer, 2017
- Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysisEuropean Journal of Cancer, 2017
- Completion Dissection or Observation for Sentinel-Node Metastasis in MelanomaThe New England Journal of Medicine, 2017
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant TherapyThe New England Journal of Medicine, 2016
- Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trialThe Lancet Oncology, 2016